Over the past few years, novel GBM therapies have emerged, including gamma knife, proton beam, tumor-treating fields, and inhibitors targeting epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), receptor tyrosine kinases (RTKs), and the PI3K pathway [6,7,8,9,10,11,12]. Here, NTRK1 is linked to glioblastoma.